Dermatology · PANCE / PANRE

Acne Vulgaris

Chronic inflammatory disorder of the pilosebaceous unit driven by androgens, sebum, keratinization, and Cutibacterium acnes.

Also known as: acne, comedonal acne, inflammatory acne, nodulocystic acne, pimples

Overview

A chronic inflammatory disorder of the pilosebaceous unit characterized by comedones, papules, pustules, nodules, and cysts, distributed on the face, chest, and back.

Epidemiology

Affects up to 85% of adolescents; peak incidence ages 12-24. Persists into adulthood in ~25% of women and ~12% of men. More severe and scarring forms in male adolescents.

Try two board-style Acne Vulgaris questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1DermatologyMedium
A 16-year-old male presents with worsening acne on the face and back despite 3 months of over-the-counter benzoyl peroxide. On examination, there are numerous open and closed comedones, inflammatory papules, pustules, and several tender deep nodules and cysts, with early pitted scarring across both cheeks and the upper back. He reports significant distress about his appearance. Which of the following is the most appropriate next step in management?
  • AOral isotretinoin
  • BOral doxycycline
  • CTopical tretinoin
  • DTopical clindamycin
Reveal answer & full explanation
Correct answer: A — Oral isotretinoin
  • AOral isotretinoin
  • BOral doxycycline
  • CTopical tretinoin
  • DTopical clindamycin

Why Oral isotretinoin is correct

  • This is severe nodulocystic acne with scarring — the principal indication for oral isotretinoin, a systemic retinoid (13-cis-retinoic acid)
  • Isotretinoin is the only acne therapy that targets all four pathogenic factors: follicular hyperkeratinization, sebum production, Cutibacterium acnes proliferation, and inflammation
  • Roughly 85 percent of patients achieve durable remission after a single course of 120 to 150 mg/kg cumulative dose over 15 to 20 weeks
  • Early scarring and failure of less aggressive therapy make prompt escalation important to prevent permanent disfigurement
  • Because the drug is teratogenic, enrollment in the iPLEDGE program with monthly monitoring is required, along with baseline and periodic lipid panels and liver function tests
  • Common adverse effects include cheilitis, dry skin, and hypertriglyceridemia

Why the others are wrong

  • B) Oral doxycycline — appropriate for moderate inflammatory acne but inadequate for nodulocystic disease that is already scarring and would not address the depth of involvement here
  • C) Topical tretinoin — a first-line agent for comedonal and mild inflammatory acne and useful adjunctively, but as a single topical agent it cannot control widespread nodular disease
  • D) Topical clindamycin — best used in combination with benzoyl peroxide for mild-to-moderate inflammatory acne; far too weak for this presentation, and clindamycin used alone also promotes bacterial resistance
Question 2DermatologyMedium
A 25-year-old female has severe nodulocystic acne on the face, chest, and back that has failed topical benzoyl peroxide, topical retinoids, and two 3-month courses of oral antibiotics. She has no history of inflammatory bowel disease or depression. Which of the following is the most effective treatment?
  • ASpironolactone
  • BCombined oral contraceptive
  • CIsotretinoin
  • DIntralesional triamcinolone
Reveal answer & full explanation
Correct answer: C — Isotretinoin
  • ASpironolactone
  • BCombined oral contraceptive
  • CIsotretinoin
  • DIntralesional triamcinolone

Why Isotretinoin is correct

  • Isotretinoin is the most effective treatment for severe nodulocystic acne and acne unresponsive to antibiotics
  • Mechanism: reduces sebaceous gland size and sebum production by 70-90%, normalizes follicular keratinization, and is anti-inflammatory
  • Dose: 0.5-1 mg/kg/day for 16-20 weeks; cumulative dose 120-150 mg/kg for optimal outcomes
  • About 85% of patients achieve long-term remission after one course

Why the others are wrong

  • Spironolactone — is a useful adjunct for hormonal acne in females but is less effective than isotretinoin for nodulocystic disease (right-concept-wrong-drug)
  • Combined oral contraceptive — is an adjunct for hormonal female acne but less effective than isotretinoin for severe nodulocystic disease (undertreatment)
  • Intralesional triamcinolone — treats individual cystic lesions, not widespread disease across the face, chest, and back (right-tool-wrong-scope)

Additional high-yield points

  • iPLEDGE is mandatory: two forms of contraception (Category X teratogen), monthly pregnancy tests, and monthly LFT and fasting lipid monitoring
  • Common side effects: cheilitis (near universal), xerosis, epistaxis, arthralgias
  • Isotretinoin is contraindicated in pregnancy
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Acne Vulgaris outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Adolescence and pubertal androgen surge
  • Family history of acne
  • Polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, other hyperandrogenism
  • Medications: anabolic steroids, lithium, phenytoin, isoniazid, high-dose B12, corticosteroids (steroid acne)
  • Mechanical occlusion (helmets, headbands), comedogenic cosmetics
  • High glycemic load diet and dairy (weak association)

Pathophysiology

Four-step pathogenesis: (1) androgen-driven sebum overproduction, (2) follicular hyperkeratinization → microcomedone, (3) proliferation of Cutibacterium (Propionibacterium) acnes within the lipid-rich follicle, (4) innate immune activation via TLR-2 → perifollicular inflammation. Rupture of distended follicles spills contents into the dermis, producing inflammatory papules, pustules, nodules, and scarring.

Clinical presentation

Symptoms

  • Visible facial, chest, or back lesions; mild tenderness with inflammatory papules and nodules
  • Psychosocial distress, anxiety, depression — disproportionate to objective severity in many patients
  • Post-inflammatory hyperpigmentation in skin of color; erythema and scarring after resolution

Signs / physical exam

  • Open comedones (blackheads) — dilated follicles with oxidized keratin plug
  • Closed comedones (whiteheads) — small flesh-colored papules with intact follicular orifice
  • Inflammatory papules and pustules
  • Nodules and cysts (>5 mm) — risk of permanent scarring
  • Ice-pick, boxcar, or rolling atrophic scars; hypertrophic/keloid scars on chest, back, jaw

Classic findings

Mixed comedonal and inflammatory lesions in seborrheic distribution (forehead, nose, cheeks, chin, upper chest and back).

Differential diagnosis

  • Rosacea — Centrofacial erythema and telangiectasias, NO comedones, triggers include heat/alcohol/spice; onset typically age 30-50
  • Perioral dermatitis — Small papules/pustules around mouth sparing the vermilion border; often history of topical steroid use
  • Folliculitis (bacterial or Pityrosporum) — Monomorphous follicular pustules, often on trunk/shoulders; Pityrosporum responds to antifungals, not antibiotics
  • Acne fulminans / acne conglobata — Severe nodulocystic disease with fever, arthralgia, leukocytosis (fulminans); interconnected sinus tracts (conglobata)
  • Hidradenitis suppurativa — Painful nodules and sinus tracts in axillae, groin, inframammary folds; no comedones except double-headed open comedones
  • Drug-induced acneiform eruption — Sudden monomorphic eruption after steroids, EGFR inhibitors, lithium, isoniazid; no true comedones
  • Keratosis pilaris — Rough follicular papules on extensor arms, thighs, cheeks; no inflammation or pustules

Diagnostic workup

Diagnostic criteria

Clinical diagnosis based on lesion morphology and distribution. Severity graded as mild (comedonal ± few inflammatory papules), moderate (numerous papules/pustules ± few nodules), or severe (widespread nodulocystic disease, scarring, or failure of prior therapy).

Labs

  • Generally clinical diagnosis — no routine labs
  • If suspect hyperandrogenism (sudden severe acne, hirsutism, menstrual irregularity, alopecia): total/free testosterone, DHEAS, 17-OH progesterone, LH/FSH ratio, prolactin
  • Baseline LFTs and lipid panel before starting isotretinoin; pregnancy testing per iPLEDGE program

Imaging

  • Not indicated for routine acne
  • Pelvic ultrasound if PCOS suspected

Diagnostic algorithm

SeverityLesion ProfileStepwise Therapy
Mild comedonalOpen/closed comedones, few papulesTopical retinoid ± BPO
Mild-moderate inflammatoryNumerous papules/pustulesTopical retinoid + BPO + topical antibiotic
ModeratePapules, pustules, few nodules, truncal involvementAbove + oral antibiotic (doxycycline) ± hormonal therapy (women)
Severe / scarring / refractoryWidespread nodulocystic, sinus tracts, scarringOral isotretinoin (iPLEDGE) ± short steroid course
Severity-based stepwise therapy for acne vulgaris (AAD 2024).

Treatment

First-line

  • Mild comedonal: topical retinoid — tretinoin 0.025-0.1%, adapalene 0.1-0.3%, tazarotene 0.05-0.1% (apply at night; avoid in pregnancy except adapalene category C; start every other night to limit irritation)
  • Mild-moderate inflammatory: benzoyl peroxide 2.5-10% ± topical antibiotic — clindamycin 1%, erythromycin 2% (always combine antibiotic with BPO to prevent resistance)
  • Fixed-dose combinations: adapalene/BPO, clindamycin/BPO, clindamycin/tretinoin improve adherence
  • Moderate: add oral antibiotic for 3-4 months — doxycycline 50-100 mg BID or minocycline 50-100 mg BID (sarecycline as alternative); avoid in children <8 yrs and pregnancy
  • Hormonal therapy in women: combined oral contraceptive (norgestimate/ethinyl estradiol, drospirenone/EE) or spironolactone 50-200 mg/day (monitor K+, avoid in pregnancy — teratogenic)

Severe nodulocystic / scarring / treatment-refractory

  • Oral isotretinoin 0.5-1.0 mg/kg/day × 5-7 months, cumulative dose 120-150 mg/kg
  • iPLEDGE enrollment required — monthly pregnancy tests and 2 forms of contraception in females of reproductive potential
  • Monitor LFTs, lipids, CBC at baseline and during therapy; counsel on dryness, photosensitivity, depression/mood changes, IBD signal (debated)

Acne fulminans

  • Systemic corticosteroids (prednisone 0.5-1 mg/kg/day) for 4-6 weeks, then overlap with low-dose isotretinoin starting at 0.1 mg/kg/day and titrate

Second-line / adjunct

  • Topical clascoterone 1% cream BID — first topical androgen receptor inhibitor approved for acne
  • Topical dapsone 5-7.5% — useful in adult female acne
  • Azelaic acid 15-20% — antimicrobial, anti-inflammatory, brightening (helpful for PIH)
  • Intralesional triamcinolone 2.5-5 mg/mL for individual nodules/cysts
  • Procedural: chemical peels, light/laser therapy, comedone extraction; scar revision with subcision, microneedling, fractional laser, dermabrasion, fillers

Complications

  • Permanent scarring (atrophic, hypertrophic, keloid)
  • Post-inflammatory hyperpigmentation, especially in Fitzpatrick IV-VI skin
  • Depression, anxiety, body dysmorphic disorder, suicidality
  • Isotretinoin teratogenicity (microtia, CNS, cardiac malformations)
  • Tetracycline-class adverse effects: photosensitivity, pseudotumor cerebri, esophagitis, vestibular toxicity (minocycline), drug-induced lupus and pigmentation (minocycline)

PANCE pearls

  • Comedones are the pathognomonic primary lesion of acne — their absence should prompt reconsideration of the diagnosis (especially rosacea or folliculitis).
  • Never combine isotretinoin with tetracyclines — risk of pseudotumor cerebri.
  • Spironolactone is the most underused effective therapy for adult female acne; do not require routine K+ monitoring in healthy young women on stable doses (AAD 2024 update).
  • Topical retinoids are foundational at every severity tier and during maintenance — do not stop them when adding other therapies.
  • Sudden-onset severe acne with hirsutism or virilization in an adult woman warrants endocrine workup for ovarian or adrenal tumor.

References

  • AAD 2024 — Guidelines of Care for the Management of Acne Vulgaris (Reynolds et al., J Am Acad Dermatol 2024)
  • Global Alliance 2018 — Practical Management of Acne for Clinicians: An International Consensus from the Global Alliance to Improve Outcomes in Acne (Thiboutot et al., J Am Acad Dermatol 2018)
  • iPLEDGE — iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) Program — US FDA

Practice Dermatology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.